These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ mBio; 2018 May; 9(3):. PubMed ID: 29739902 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Sarosiek KA; Cavallin LE; Bhatt S; Toomey NL; Natkunam Y; Blasini W; Gentles AJ; Ramos JC; Mesri EA; Lossos IS Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13069-74. PubMed ID: 20615981 [TBL] [Abstract][Full Text] [Related]
4. EZH2 Inhibition by DS3201 Triggers the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle and Potentiates the Effects Induced by SAHA in Primary Effusion Lymphoma Cells. Gonnella R; Collura F; Corrado V; Di Crosta M; Santarelli R; Cirone M Viruses; 2024 Sep; 16(9):. PubMed ID: 39339966 [TBL] [Abstract][Full Text] [Related]
5. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074 [TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820 [TBL] [Abstract][Full Text] [Related]
7. Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma. Mohanty S; Kumar A; Das P; Sahu SK; Choudhuri T Apoptosis; 2017 Sep; 22(9):1098-1115. PubMed ID: 28653223 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Lan K; Murakami M; Bajaj B; Kaul R; He Z; Gan R; Feldman M; Robertson ES Cancer Biol Ther; 2009 Nov; 8(22):2136-43. PubMed ID: 19783901 [TBL] [Abstract][Full Text] [Related]
10. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines. Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625 [TBL] [Abstract][Full Text] [Related]
11. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus. Zhang YJ; Patel D; Nan Y; Fan S Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956 [TBL] [Abstract][Full Text] [Related]
14. Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma. Watanabe T; Nakamura S; Ono T; Ui S; Yagi S; Kagawa H; Watanabe H; Ohe T; Mashino T; Fujimuro M Biochem Biophys Res Commun; 2014 Aug; 451(1):93-100. PubMed ID: 25063029 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447 [TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939 [TBL] [Abstract][Full Text] [Related]
17. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988 [TBL] [Abstract][Full Text] [Related]
19. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells. Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models. Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]